| Title |
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
|
|---|---|
| Published in |
Clinical Interventions in Aging, September 2008
|
| DOI | 10.2147/cia.s2046 |
| Pubmed ID | |
| Authors |
Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias |
| Abstract |
Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Russia | 1 | 1% |
| Germany | 1 | 1% |
| Taiwan | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 96 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 15 | 15% |
| Student > Bachelor | 15 | 15% |
| Researcher | 13 | 13% |
| Student > Ph. D. Student | 12 | 12% |
| Other | 8 | 8% |
| Other | 16 | 16% |
| Unknown | 21 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 8% |
| Biochemistry, Genetics and Molecular Biology | 6 | 6% |
| Agricultural and Biological Sciences | 6 | 6% |
| Nursing and Health Professions | 5 | 5% |
| Other | 19 | 19% |
| Unknown | 27 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2023.
All research outputs
#17,286,645
of 25,374,917 outputs
Outputs from Clinical Interventions in Aging
#1,255
of 1,968 outputs
Outputs of similar age
#82,269
of 95,706 outputs
Outputs of similar age from Clinical Interventions in Aging
#10
of 13 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,968 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,706 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.